Navitoclax, which also inhibits BCL-XL, had a broader activity against the ALL xenograft than venetoclax, although there was a correlation between the response to the two drugs in individual xenografts, suggesting BCL-2 inhibition also contributes to the cytotoxic effect. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.